Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’

This article was originally published in The Pink Sheet Daily

Executive Summary

Negotiations for generic drug user fee reauthorization open with FDA saying it doesn't want a large number of small tweaks that will increase program complexity.

You may also be interested in...



Generic User Fee Negotiations May Be Falling Behind Schedule

FDA and industry look to speed up the talks with GDUFA financial issues still to come.

Review Times Remain A GDUFA II Topic

Talks continue to include ANDA review times and metrics, increasing potential for more changes.

Senate Medical Innovation Bill: Will Slow, Small And Steady Win The Race?

Compared to House's 21st Century Cures package, Senate's Healthier Americans initiative is tiny, but if nothing else bills will lay important groundwork for user fee legislation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel